Anavex Life Sciences Reports PK and PD Data from Phase 2a Trial of ANAVEX®2-73 in Mild-to-Moderate Alzheimer’s Disease Patients; Conference call today at 8:30am ET
Anavex Life Sciences will be presenting at the Ladenburg Thalmann 2017 Healthcare Conference on Sept 26 at 3:30pm in New York, NY at the Sofitel Hotel.
Anavex Life Sciences will be presenting at the CNS Diseases Summit 2017 from Sept 11-12 in Boston, Massachusetts at the Hyatt Regency Boston.
Anavex Life Sciences Appoints Distinguished Researcher in Neurology and Epilepsy to Scientific Advisory Board
Anavex Life Sciences will be attending the Bio International Convention from June 19th to 22nd in San Diego, California at the San Diego Convention Center.
Anavex Life Sciences Reports New Data for ANAVEX 2-73 in Neurodevelopmental Disorders Including Angelman Syndrome − Data Presented at Antiepileptic Drug Trials XIV 2017 Conference
Antiepileptic Drug Trials XIV 2017 Conference in Aventura, Florida on May 19th, 2017. View Presentation